Search hospitals > New Jersey > Camden
Md Anderson Cancer Center At Cooper
Claim this profileCamden, New Jersey 08103
Global Leader in Lung Cancer
Global Leader in Parotid Gland Cancer
Conducts research for Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Cervical Adenocarcinoma
58 reported clinical trials
10 medical researchers
Summary
Md Anderson Cancer Center At Cooper is a medical facility located in Camden, New Jersey. This center is recognized for care of Lung Cancer, Parotid Gland Cancer, Breast Cancer, Ovarian Cancer, Cervical Adenocarcinoma and other specialties. Md Anderson Cancer Center At Cooper is involved with conducting 58 clinical trials across 111 conditions. There are 10 research doctors associated with this hospital, such as David P. Warshal, Farhad Ravandi-Kashani, Jamin C. Morrison, and Kiran Naqvi.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Parotid Gland Cancer
Global LeaderStage II
Stage III
Top PIs
David P. WarshalCooper Hospital University Medical Center2 years of reported clinical research
Studies Cervical Adenocarcinoma
Studies Ovarian Cancer
15 reported clinical trials
33 drugs studied
Farhad Ravandi-KashaniM D Anderson Cancer Center4 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
11 reported clinical trials
24 drugs studied
Jamin C. MorrisonCooper Hospital University Medical Center5 years of reported clinical research
Studies Pancreatic Cancer
Studies Colorectal Cancer
9 reported clinical trials
17 drugs studied
Kiran NaqviM D Anderson Cancer Center1 year of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
5 reported clinical trials
10 drugs studied
Clinical Trials running at Md Anderson Cancer Center At Cooper
Melanoma
Breast Cancer
Skin Cancer
Multiple Myeloma
Acute Promyelocytic Leukemia
Pneumonia
Lung Cancer
Breast cancer
Plasma Cell Neoplasm
Prostatic Neoplasm
VO + Nivolumab
for Advanced Melanoma
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Recruiting2 awards Phase 33 criteria
Lifileucel + Pembrolizumab
for Melanoma
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Md Anderson Cancer Center At Cooper?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.